Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Answer


    Rapid verdict
    The paper is a mechanistic, hypothesis-driven narrative review that centers a signaling-and-phenotype network in PDAC: KRAS β†’ MAPK/PI3K with functional/therapeutic convergence on YAP/TAZ, SFKs, and a stress/obesity-to-transcription node via CREB/ATF1, then surveys emerging targeted strategies including KRAS(ON) and YAP/TEAD inhibition plus combination logic and resistance/feedback pitfalls.



     Long Answer


    Paper Review (Scientific): Pancreatic cancerβ€”molecular pathogenesis & emerging therapeutic strategies
    Rozengurt & Eibl β€’ Signal Transduction and Targeted Therapy β€’ DOI: 10.1038/s41392-025-02499-y
    Known vs inferred (epistemic hygiene)
    • Known (as stated in the review): PDAC lethality and late diagnosis; KRAS activation as a dominant early driver; frequent co-alterations (e.g., CDKN2A, TP53, SMAD4); two broad transcriptional subtypes (classical vs basal-like/squamous) and their differential prognosis; and mechanistic links among KRAS signaling, YAP/TAZ, and Src-family kinases.
    • Inferred / model-based: that YAP/TAZ can functionally bypass KRAS in a subset of PDAC contexts and that stress/obesity converge through Ξ²-adrenergic signaling and PKA/PKD to CREB/ATF1, promoting PanIN β†’ PDAC progression.
    • Uncertain / contested (as implied by the review’s own caveats): why several pathway inhibitors underperform clinically, and which biomarkers will reliably select responsive patient subsets given feedback-driven resistance complexity.
    Paper’s central thesis (compressed)
    KRAS mutation is an early but not sufficient event; progression and therapy resistance arise from network rewiringβ€”especially KRAS–YAP/TAZ and KRAS–Src-family interactionsβ€”while obesity and chronic stress act as tumor promoters that converge on CREB/ATF1 phosphorylation to amplify malignant programs.
    Practical take-home for research design
    Translation hinges on contextual dependency (PDAC subtype & microenvironment) and on feedback-aware combination logic rather than single-pathway blocking.
    Visualizations (from the review’s extracted quantitative summaries)
    Note: Values are schematic proportions explicitly stated in the review’s extracted dataset (e.g., G12D ~45%, G12V ~35%; remaining ~20% grouped).
    Review-extracted approximate frequencies are presented as bar heights and should be treated as rough prevalence statements rather than precision estimates.
    This plot is not a claim about quantitative evidence strength; it merely visualizes how strongly themes recur in the review’s narrative flow as provided in the paper text.
    Mechanistic synthesis (KRAS–YAP/SFK + obesity/stress β†’ CREB)
    1) Initiation vs progression: why KRAS alone is insufficient
    The review explicitly argues that activating KRAS mutations are crucial for PDAC initiation and are frequent in low-grade lesions, but KRAS activation is not sufficient to drive full progression from preneoplasia (e.g., PanIN) to overt invasive PDAC.
    2) KRAS downstream network architecture: MAPK/ERK & PI3K/AKT/mTOR
    The review lays out two canonical KRAS downstream signaling modulesβ€”RAF/MEK/ERK and PI3K/AKT/mTORβ€”and ties them to proliferation, survival, and metastasis, including mTORC1 vs mTORC2 functional distinction and upstream regulators such as PTEN/TSC/Rheb.
    3) YAP/TAZ as a KRAS-bypass node (context-dependent subtype biology)
    The review presents YAP/TAZ as critical transcriptional coactivators in PDAC and argues they can both cooperate with KRAS in early stages and bypass KRAS dependency in some advanced/basal-like contexts.
    4) Src family kinases (SFKs) connect tyrosine signaling to Hippo/YAP control and to drug response outcomes
    The review describes SFKs (highlighting YES1) as upregulated in PDAC and proposes SFK–YAP regulatory routes involving Hippo-dependent effects (e.g., inhibition of LATS) and Hippo-independent effects (direct YAP Tyr357 phosphorylation), then uses this to motivate why broad SFK inhibition may yield mixed/discordant pathway effects (e.g., potential KRAS/ERK feedback reactivation) and why clinical trial outcomes can be disappointing.
    5) Obesity + chronic stress: convergence on CREB/ATF1 phosphorylation
    The review argues that obesity-related mediators and chronic stress through the sympathetic nervous system act as tumor promoters by stimulating kinase pathways (including PKA and PKD) that converge on phosphorylation of CREB/ATF1 (Ser133/Ser63), thereby promoting metaplasia/progression and providing a central integrative transcriptional node.
    Therapeutic landscape: targeted strategies and resistance logic
    KRAS targeting: from G12C to G12D and network-aware ON-state inhibition
    The review contrasts the clinical success of covalent KRAS G12C inhibitors (sotorasib/adagrasib in NSCLC) with the need for inhibitors for PDAC’s dominant G12D biology, then highlights emerging noncovalent KRAS(G12D) inhibition (e.g., MRTX1133) and broader RAS(ON) inhibitors (e.g., daraxonrasib/RMC-6236; RMC-7977) framed around expected resistance due to feedback RTK reactivation and YAP/TAZ-mediated escape.
    YAP/TEAD targeting: breaking the KRAS bypass and resistance loops
    The review frames YAP/TEAD inhibitors (including TEAD pocket disruptors and YAP–TEAD interface disruptors) as strategies to blunt both KRAS-independent maintenance and KRAS inhibitor resistance. It also discusses resistance to TEAD inhibitors via pathway reactivation (e.g., RAF/MEK/ERK β†’ FOSL1), motivating mechanistic combo thinking.
    Combination strategies: mTOR/MEK feedbacks as a generic failure mode
    A repeating explanatory theme is that pathway inhibitors can release negative feedback loops and trigger compensatory pathway activation (e.g., ERK feedback to MEK/RAF upstream nodes; mTORC1/S6K feedback on PI3K/AKT/RTKs; and AKT inhibition derepressing RTK expression), thereby enabling drug resistance.
    Skeptical critique (strengths, blind spots, and what would change the story)
    Strengths (what the review does well)
    • Mechanistic connectivity: the review repeatedly maps molecular events to phenotype and therapy response (KRAS–MAPK/PI3Kβ†’YAP/TAZ, kinase convergence β†’ CREB/ATF1, and feedback logic for resistance).
    • Context sensitivity: it emphasizes PDAC subtype biology and KRAS dependency variability (e.g., basal-like/squamous vs classical), which is crucial for targeting strategies to avoid one-size-fits-all failure.
    Blind spots / risk of overreach
    • Narrative review selection risk: as a narrative synthesis, it can overweight coherent mechanistic threads while underrepresenting counter-models or null results; the review itself acknowledges limited translational success for several targeted strategies, but it is not a formal meta-analysis.
    • Model-to-human uncertainty: it leans substantially on GEMMs/organoids and mechanistic inhibitor studies; while these can reveal causal pathways, differences in tumor microenvironment composition and drug exposure can alter the hierarchy of dependencies.
    • Biomarker causality vs correlation: suggested biomarker nodes (e.g., YAP activity, SFK/YES1, CREB phosphorylation status) may correlate with outcome yet still fail to be causal drivers in every clinical context; the review’s emphasis on feedback loops makes this a recurring translation hazard.
    What would most disprove or force revision?
    • Evidence that obesity/stress do not increase PanIN progression or PDAC aggressiveness in KRAS-initiated systems would weaken the β€œtumor promotion via CREB convergence” framing.
    • Evidence that YAP/TAZ activity cannot substitute for KRAS dependency in basal-like/squamous PDAC contexts would undermine the bypass model and reduce the rationale for YAP/TEAD-centric resistance counter-strategies.
    • Well-powered clinical datasets showing that rational, feedback-aware combination strategies do not improve outcomes in mechanistically stratified populations would suggest the dominant resistance mechanisms are different from those highlighted.


    Feedback:    

    Updated: April 05, 2026

     BGPT Paper Review


    Study Novelty

    70%

    Novelty comes from the review’s specific systems-level narrative that ties KRAS↔YAP/TAZ↔SFK signaling to obesity/stress promotion converging on CREB/ATF1 and then maps this directly onto modern KRAS(ON) and YAP/TEAD targeting plus feedback-aware resistance logic.


    Scientific Quality

    90%

    High scientific quality for a narrative review: coherent mechanistic causality, careful emphasis on KRAS dependency heterogeneity, and explicit discussion of feedback-driven resistance that plausibly explains clinical underperformance of pathway inhibition. Remaining quality constraints: narrative (not systematic/meta-analytic), and mechanistic claims are only as strong as the underlying heterogeneous evidence base.


    Study Generality

    80%

    It is broadly informative across PDAC biology (initiation, progression, microenvironment, metabolism, subtype variation) and links general cancer network principles (feedback, resistance, transcriptional coactivator hubs) to actionable therapeutic categories; however it is still PDAC-centered and anchored to a particular mechanistic axis.


    Study Usefulness

    80%

    Useful as a mechanistic briefing and hypothesis generator: it provides a testable causal scaffold (KRAS/YAP/SFK/CREB) and explains why combination approaches may be necessary due to feedback loops and resistance nodes.


    Study Reproducibility

    70%

    Reproducibility is moderate because it is a narrative synthesis without new methods or released datasets; however, the mechanistic and quantitative statements are internally referenced and the extracted numerical summaries (e.g., KRAS mutation proportions and tumor suppressor frequencies) can be reproduced by tracing the cited cohorts.


    Explanatory Depth

    80%

    Deep mechanistic explanatory structure: it lays out pathway wiring (MAPK/ERK, PI3K/AKT/mTOR, Hippo/YAP, SFK-mediated tyrosine regulation) and then adds integrative convergence via obesity/stress→β-adrenergic→PKA/PKD→CREB/ATF1, explicitly connecting these to drug sensitivity and resistance.


    🎁 Authors: Collect 451 Free Science Tokens (β‰ˆ $45.1 USD)

    Claim My Author Tokens

    Use for 112 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $45.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Build a pathway-centric feature table from the review’s extracted PDAC node summaries, then generate subtype-stratified priority rankings (KRASβ†’YAP/SFKβ†’CREB) for downstream experimental planning and literature tracebacks.



     Hypothesis Graveyard


    A simplistic β€œKRASβ†’YAP is always linear” model is less likely: the review stresses subtype/context dependence and explicit bypass/feedback circuitry, implying direct linearity across all PDAC contexts would be inconsistent with described heterogeneity.


    A β€œΞ²-adrenergic signaling drives PDAC independently of metabolic state” model is less likely: the review repeatedly links obesity (insulin/IGF, mediators like neurotensin/leptin) with SNS activation and convergence on kinase signaling, implying integration rather than independence.

     Science Art


    Paper Review: Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending